At the time of writing, Crinetics Pharmaceuticals Inc [CRNX] stock is trading at $53.25, up 0.02%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRNX shares have gain 13.95% over the last week, with a monthly amount glided 11.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $36. Previously, Stifel started tracking the stock with Buy rating on March 25, 2025, and set its price target to $60. On February 11, 2025, TD Cowen initiated with a Buy rating. Wolfe Research started tracking the stock assigning a Peer Perform rating. Jefferies upgraded its rating to a Buy but $55 remained the price target by the analyst firm on January 22, 2025. Citigroup started tracking with a Buy rating for this stock on March 06, 2024, and assigned it a price target of $68. In a note dated January 16, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $50 on this stock.
For the past year, the stock price of Crinetics Pharmaceuticals Inc fluctuated between $24.10 and $57.99. Currently, Wall Street analysts expect the stock to reach $97.83 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $53.25 at the most recent close of the market. An investor can expect a potential return of 83.72% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -311.3%, Pretax Profit Margin comes in at -275.63%, and Net Profit Margin reading is -275.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.35 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] has a current ratio of 15.12. Also, the Quick Ratio is 15.12, while the Cash Ratio stands at 1.5. Considering the valuation of this stock, the price to sales ratio is 3567.14, the price to book ratio is 4.70.
Transactions by insiders
Recent insider trading involved Kalofonos Isabel, Chief Commercial Officer, that happened on Jan 05 ’26 when 2500.0 shares were sold. Officer, ISABEL KALOFONOS completed a deal on Jan 05 ’26 to buy 2500.0 shares. Meanwhile, Officer DANA PIZZUTI bought 5000.0 shares on Jan 02 ’26.
